Oxford University in Britain started human clinical trials Thursday, April 23, for a vaccine against the new coronavirus, with the ambitious hope of making it available to the public this year.
READ MORE: In its first phase, half of the 1,112 volunteers will receive the potential vaccine against COVID-19, the other half a control vaccine to test its safety and efficacy. The volunteers, ages 18 to 55, are in good health, have not tested positive for COVID-19 and are not pregnant or breastfeeding.
British Health Secretary Matt Hancock announced Tuesday that two separate British research teams are making significant progress on a COVID-19 vaccine.
At a news briefing in London, Hancock said researchers at both the Imperial College of London and Oxford University had are moving into the trial stage with their potential vaccines.
He said the Oxford team, which has been working closely with Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) was prepared to begin conducting clinical trials on people this week. He said the government is allocating about $25 million to fund their effort.
He said the government is also allocating more than $27 million to Imperial College to fund phase two of its clinical trials, and for it to start a phase three trial. (VOA/AP)